Arax Advisory Partners’s Bristol-Myers Squibb Rights CELG.RT Stock Holding History

Arax Advisory Partners’s Portfolio CELG.RT Stock Details CELG.RT Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q3	$13.6K	Buy	+109,175	New	+$12.1K	﹤0.01%	4248

Other funds holding CELG.RT

Birchview Capital Burlington, Vermont $173M AUM 89.27% 1-Year Est. Return

Davenport & Co Richmond, Virginia $19.9B AUM 12.67% 1-Year Est. Return

Purkiss Capital Advisors Ridgefield, Connecticut $268M AUM 23.98% 1-Year Est. Return

Private Advisor Group Morristown, New Jersey $29.9B AUM 19.22% 1-Year Est. Return

UBS Group Zurich, Switzerland $765B AUM 28.39% 1-Year Est. Return

Northwestern Mutual Wealth Management Milwaukee, Wisconsin $192B AUM 13.66% 1-Year Est. Return

Rothschild Investment LLC Chicago, Illinois $2.69B AUM 27.79% 1-Year Est. Return

Oakworth Capital Birmingham, Alabama $2.12B AUM 16.07% 1-Year Est. Return

Morgan Stanley New York $1.96T AUM 27.49% 1-Year Est. Return

JP Morgan Chase New York $1.84T AUM 33.86% 1-Year Est. Return

Arax Advisory Partners's CELG.RT Position: Q3 2026 in Review

Arax Advisory Partners opened a new position in Bristol-Myers Squibb Rights (CELG.RT) in Q3 2026: 109,175 shares worth $13.6K. The stake represents ﹤0.01% of the portfolio and ranks #4248 among its holdings.

12 funds tracked by Wall St. Rank hold CELG.RT as of Q3 2026.

Arax Advisory Partners held 109,175 shares of Bristol-Myers Squibb Rights worth $13.6K as of Q3 2026.
Bristol-Myers Squibb Rights was a new Arax Advisory Partners position in Q3 2026.
Bristol-Myers Squibb Rights made up ﹤0.01% of Arax Advisory Partners's portfolio in Q3 2026, its #4248 holding.
12 funds tracked by Wall St. Rank held Bristol-Myers Squibb Rights as of Q3 2026.

Based on Arax Advisory Partners's 13F filing for Q3 2026, filed 12 Nov 2026.